Latest Conference Articles

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

Teriflunomide was an effective first-line therapy for RRMS and a suitable switch therapy in real-world data.

The TOPIC study results additionally showed a strong association between CGMV loss and CDMS conversion.

Tanuja Chitnis, MD, spoke about the first-of-its-kind PARADIGMS trial, and pediatric multiple sclerosis, as well as how it differs from the condition in adults.

Subgroup analysis revealed a greater improvement for patients with baseline visual impairment.

Alemtuzumab showed significant reductions in MRI lesions and slowed brain volume loss in 5-year results for RRMS.

Martin Weber, MD, spoke about the role that B cells and antibodies play in the treatment of multiple sclerosis.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

As drug costs continue to rise, many are hoping generics will bring relief. But will they?

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, talks about treatment options for Candida auris and multi-drug resistant treatment options.

Tom Chiller, MD, MPH, Mycotic Diseases Branch, Centers for Disease Control and Prevention, discusses Candida auris.

The sc2Wear Infusor allows the opportunity to deliver furosemide subcutaneously and at home, to keep HF patients in need of diuresis out of the hospital.

In response to patient concerns about dosing options and duration of effect, researchers at Shire Pharmaceuticals created Mydayis for the treatment of ADHD symptoms.

Psychedelics like psilocybin have been receiving attention from psychiatrists on and off for decades. Here's what we've learned, and what's on the horizon.

The ROPA-DOP trial showed that low-dose dopamine had an insignificant impact on patient renal function, nor a significant trend toward greater diuresis.

Scott Solomon, MD, and Alvin Chandra, MD, discuss the findings of the PARADIGM-HF and QoL trial, and sacubitril's effect on HF patients quality of life.

Parental rejection, abandonment, physical and sexual abuse double the victim's rates of depression, inflammation, metabolic disorders and chronic medical illnesses.

Patients struggling with addiction can be difficult to treat. Following best practices can help simplify a complex process.

Lisa Rathman, MSN, of Lancaster General Hospital, discusses the benefits of subcutaneous furosemide in nursing homes and facilities outside the hospital.

Gregg Fonarow, MD; David Aguilar, MD; Rob Mentz, MD; and James Januzzi, MD, discuss the unexpected and exciting use of SGLT-2 inhibitors to treat heart failure.

Rob Mentz, MD, of Duke University Medical School, discusses the CANVAS trial and the pursuit of using SGLT-2 inhibitors to treat heart failure.

The drug showed improved symptoms across multiple doses in a 6-month study.

Doris Greenberg, MD, discusses the fine line between Asperger's Syndrome and Autism Spectrum Disorder.

Raj Maturi, MD, talks about the use of sirolimus in combination with aflibercept for patients with chronic AMD.